243 related articles for article (PubMed ID: 29623478)
1. Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.
Jawed I; Velarde M; Därr R; Wolf KI; Adams K; Venkatesan AM; Balasubramaniam S; Poruchynsky MS; Reynolds JC; Pacak K; Fojo T
Cell Mol Neurobiol; 2018 Jul; 38(5):1099-1106. PubMed ID: 29623478
[TBL] [Abstract][Full Text] [Related]
2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
3. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
4. Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas.
Asai S; Katabami T; Tsuiki M; Tanaka Y; Naruse M
Horm Cancer; 2017 Apr; 8(2):108-118. PubMed ID: 28108930
[TBL] [Abstract][Full Text] [Related]
5. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
6. Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?
Gul AE; Keser SH; Barisik NO; Gurbuz YS; Sensu S; Erdogan N
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1721-1729. PubMed ID: 34181326
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma.
Tanabe A; Naruse M; Nomura K; Tsuiki M; Tsumagari A; Ichihara A
Horm Cancer; 2013 Apr; 4(2):103-10. PubMed ID: 23361939
[TBL] [Abstract][Full Text] [Related]
8. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.
Sait S; Pandit-Taskar N; Modak S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28409892
[No Abstract] [Full Text] [Related]
9. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma.
He J; Makey D; Fojo T; Adams KT; Havekes B; Eisenhofer G; Sullivan P; Lai EW; Pacak K
Endocrine; 2009 Oct; 36(2):189-93. PubMed ID: 19618298
[TBL] [Abstract][Full Text] [Related]
10. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.
Astuti D; Latif F; Dallol A; Dahia PL; Douglas F; George E; Sköldberg F; Husebye ES; Eng C; Maher ER
Am J Hum Genet; 2001 Jul; 69(1):49-54. PubMed ID: 11404820
[TBL] [Abstract][Full Text] [Related]
11. Risk of metastatic pheochromocytoma and paraganglioma in
Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
[TBL] [Abstract][Full Text] [Related]
12. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
13. Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies.
Barbolosi D; Crona J; Serre R; Pacak K; Taieb D
PLoS One; 2018; 13(8):e0201303. PubMed ID: 30106970
[TBL] [Abstract][Full Text] [Related]
14. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
Kornaczewski ER; Pointon OP; Burgess JR
Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
[TBL] [Abstract][Full Text] [Related]
15. Superiority of
Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis.
Niemeijer ND; Alblas G; van Hulsteijn LT; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Nov; 81(5):642-51. PubMed ID: 25041164
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?
Taïeb D; Sebag F; Barlier A; Tessonnier L; Palazzo FF; Morange I; Niccoli-Sire P; Fakhry N; De Micco C; Cammilleri S; Enjalbert A; Henry JF; Mundler O
J Nucl Med; 2009 May; 50(5):711-7. PubMed ID: 19372492
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel SDHB c.563 T > C mutation responsible for Paraganglioma syndrome and genetic analysis of the SDHB gene in China: a case report.
Chen H; Yao W; He Q; Yu X; Bian B
BMC Med Genet; 2020 May; 21(1):116. PubMed ID: 32460727
[TBL] [Abstract][Full Text] [Related]
19. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
Huang H; Abraham J; Hung E; Averbuch S; Merino M; Steinberg SM; Pacak K; Fojo T
Cancer; 2008 Oct; 113(8):2020-8. PubMed ID: 18780317
[TBL] [Abstract][Full Text] [Related]
20. An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline
Alzahrani AS; Bin Nafisah A; Alswailem M; Moria Y; Poprawski D; Al-Hindi H; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1273093. PubMed ID: 38152133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
